Bionomics Investor Presentation Deck
Ongoing Strategic Collaboration with Merck & Co.
MSD
Collaboration
Overview
Development
Updates
Bionomics
ā
Entered into in 2014 to develop a7 receptor PAMs targeting cognitive dysfunction associated with Alzheimer's disease and
other central nervous system conditions
Merck funds all R&D activities including clinical development and WW commercialization of any products from collaboration
Milestone payments of US$20M upfront and US$10M in 2017 when 1st compound entered Phase 1 clinical trials
Eligible to receive up to US$465M in additional development and commercial milestone payments plus royalties
Includes 2 candidates which are PAMs of the a7 receptor in early-stage Phase 1 safety and biomarker clinical trials for
treating cognitive impairment
The 1st compound has completed Phase 1 safety clinical trials in healthy subjects and there are ongoing plans for further biomarker
studies
In 2020, a second molecule that showed an improved potency profile in preclinical animal models was advanced by Merck into
Phase 1 clinical trials
MERCK
PARTNERSHIP
Snapshot of Early BNC375 Studies
A
1001
Recognition (%)
80-
60-
40-
20-
*
Veh
Wang et al. J Pharmacol Exp Ther 373:311-324, May 2020 https://pubmed.ncbi.nlm.nih.gov/32094294/
PAM = Positive allosteric modulator
MSD = A tradename of Merck & Co., Inc., Kenilworth NJ USA
-- Scopolamine (1 mpk, IP) ---
0
0.01 0.1 1 10 Don
BNC375 (mg/kg, PO)
A
% Correct
Difficult Trials
100-
80-
60-
40-
20-
*
V
0
Scopolamine
0.1
1
BNC375 (mg/kg, PO)
10
% Correct
Difficult Trials
100-
50-
0
*
0
3
BNC 375 (mg/kg, IM)
21View entire presentation